Skip to main content

Mycosis Fungoides News

FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and Sézary Syndrome

August 8, 2018 – The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory...

Seattle Genetics Announces FDA Approval of Adcetris (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for...

Ceptaris Receives FDA Approval for Valchlor (mechlorethamine) Gel for the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma

MALVERN, PA (August 26, 2013) – Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

prednisone, methotrexate, dexamethasone